| Purpose: With the increase of Her-2 positive patients,the efficacy and adverse reactions of anti-Her-2 drugs.The cardiac toxicity caused by anti-HER-2 drugs in clinical practice is a common problem in tumour patients.Clinical practice pays more attention to enhancing the curative effect and reducing the adverse reactions of patients after medication.If the adverse reactions are aggravated,the dose and frequency of treatment for tumour patients will be limited.Therefore,this study takes Her-2 positive patients as the research object to observe the clinical efficacy and safety of Chaihu plus keel oyster soup combined with anti-HER-2drugs in the treatment of Her-2 positive patients(qi stagnation syndrome).Material and Methods:According to the inclusion criteria,61 inpatients in the department of oncology were selected as clinical research objects and divided into 30 cases in the combined TCM group and 31 cases in the control group according to the ir own wishes.All the subjects were from the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.The combined Chinese medicine group was given bupleurum keel Oyster soup orally from the beginning of targeted therapy.The contr ol group only received targeted therapy,21 days for one cycle.There was no significa nt difference in baseline between the two groups before treatment,which was compara ble.Objective response rate(ORR),disease control rate(DCR),tumor marker CEA,C A125,CA153 levels,and total scores of TCM symptoms were observed in the two gr oups.Survival measures: progression-free survival time(PFS)was recorded.Toxic reac tion indexes: myocardial enzyme profile(CK,CK-MB,LDH),electrocardiogram,cardia c color ultrasound(LVEF,LVEED,LVESD,LAD,IVST,PWT);Number of allergic re actions,skin reactions and gastrointestinal reactions.Safety indicators: blood routine an d liver and kidney function were observed.To evaluate the efficacy and safety of bup leurum plus keel oyster soup.Results:1.Baseline comparison: There were no significant differences between the two groups in terms of tumor type,metastasis,tumor stage,treatment plan,gender and age(P > 0.05).2.Clinical efficacy: There were significant differences in ORR and DCR between the two groups(P < 0.05),and the combined group was significantly better than the control group.3.Tumor marker levels: The levels of CEA,CA125 and CA153 in the two groups were significantly lower than those in the control group when compared between groups(P < 0.05).4.TCM symptom score: The total TCM symptom score of the two groups was compared between groups,and the symptom score of the combined TCM group was significantly lower than that of the control group after treatment(P < 0.05).5.Progression-free survival: After analysis,the m PFS of the combined group was 30 months,and that of the control group was 19 months,and the progression time of the control group was significantly earlier than that of the combined group(P < 0.05).6.Electrocardiogram: The number of patients with abnormal electrocardiogram after treatment was recorded between the two groups,and no significant difference was found(P >0.05).7.Myocardial enzyme spectrum: The levels of CK,CK-MB and LDH in the two groups were compared between the two groups,and it was found that there was no statistical significance after 2 cycles of treatment(P > 0.05),but there was a significant difference between the two groups after 4 cycles of treatment.(P < 0.05).8.Cardiac color ultrasound: LVEF,LVESD and LAD values of the two groups were compared between the two groups.The results showed that no significant differences were observed after 2 weeks(P > 0.05),and significant differences were observed after 4 cycles(P< 0.05).There were no significant differences in LVEDD,IVST and PWT values between the two groups after 2 cycles and 4 cycles(P > 0.05).9.Skin reaction: The number of people who had skin reactions after treatment in the two groups was compared,and the results showed that the difference was statistically significant(P<0.05).10.Gastrointestinal reaction: The number of people who had gastrointestinal reaction after treatment in the two groups was compared,and the results showed that the difference was statistically significant(P<0.05).11.Allergic reaction: The number of people who had allergic reactions after treatment in the two groups was compared,and the results showed that the difference showed no statistical significance(P>0.05).12.Safety evaluation: comparing the blood routine,liver function and kidney function of the two groups of patients before and after treatment,the results showed no statistical significance(P>0.05).Conclusion:1.Chaihu Longgumuli decoction can improve the clinical effect,reduce the level of Tumor marker,improve the symptoms of traditional Chinese medicine,and prolong the non-progression survival time of patients with Qi stagnation.2.Chaihu longgu muli decoction can improve the cardiac toxicity,gastrointestinal toxicity and skin toxicity induced by targeted therapy,and can relieve the pain of patients and improve their quality of life.3.No significant bone marrow suppression and hepatorenal toxicity were observed. |
PDF Full Text Request